Literature DB >> 3327562

Rheology of paraproteinaemias and the plasma hyperviscosity syndrome.

T Somer.   

Abstract

The proper understanding of the causes, pathophysiology, diagnosis and management of the plasma hyperviscosity syndrome is based on good knowledge of malignant paraproteinaemias, properties of immunoglobulins, rheology of blood in the microcirculation, and modern plasma separation techniques. This multifaceted syndrome complicates less than ten per cent of IgA and IgG myelomas, and up to one-third of Waldenström's macroglobulinaemias. A few cases of HVS have also been reported in association with polyclonal hypergammaglobulinaemias. Excessive paraproteinaemia may cause the plasma HVS, especially when paraproteins are extraordinarily large, asymmetrical or cryosensitive, or if they aggregate into hyperviscous macroaggregates. The resultant severe microcirculatory impairment is mainly due to the combined effects of plasma hyperviscosity, significant plasma volume expansion and intense red cell aggregation. The individually variable general symptoms, bleeding tendency, ocular, neurological, cardiovascular, and renal manifestations and laboratory parameters of the HVS are summarized briefly. The majority of patients present hyperviscosity manifestations when the plasma viscosity exceeds 5-6 mPa.s. Plasmapheresis or plasma exchange have established themselves as efficient and safe modes of therapy of hyperviscosity and hypervolaemia. The therapeutic guidelines for the plasma HVS are briefly discussed with regard to recent experience with developing plasma separation techniques. Diagnostic and therapeutic advances combined with increasing haemorheological knowledge have greatly improved the proper management of this potentially lethal complication of paraproteinaemias.

Entities:  

Mesh:

Year:  1987        PMID: 3327562     DOI: 10.1016/s0950-3536(87)80021-5

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  9 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

2.  Extended photoacoustic transport model for characterization of red blood cell morphology in microchannel flow.

Authors:  Nasire Uluc; Mehmet Burcin Unlu; Gultekin Gulsen; Hakan Erkol
Journal:  Biomed Opt Express       Date:  2018-05-23       Impact factor: 3.732

3.  Molecular size heterogeneity of immunoglobulins in health and disease.

Authors:  P J Roberts-Thomson; K Shepherd
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Anti-Sa cold agglutinin of IgA class requiring plasma-exchange therapy as early manifestation of multiple myeloma.

Authors:  A Pereira; R Mazzara; L Escoda; I Alcorta; B Nomdedeu; D Roelcke
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

5.  Hyperviscosity in HIV infected children--a potential hazard during intravenous immunoglobulin therapy.

Authors:  R A Hague; O B Eden; P L Yap; J Y Mok; P Rae
Journal:  Blut       Date:  1990 Aug-Sep

Review 6.  [Therapeutic plasma exchange 1996].

Authors:  U Weber; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-10-15

7.  In silico biophysics and hemorheology of blood hyperviscosity syndrome.

Authors:  Elahe Javadi; Yixiang Deng; George Em Karniadakis; Safa Jamali
Journal:  Biophys J       Date:  2021-06-02       Impact factor: 3.699

8.  Polyclonal hyperviscosity syndrome in IgG4-related disease and associated conditions.

Authors:  Luke Yc Chen; Patrick Cw Wong; Shinji Noda; David R Collins; Gayatri M Sreenivasan; Robert C Coupland
Journal:  Clin Case Rep       Date:  2015-02-02

9.  Association between left ventricular function and paraprotein type in patients with multiple myeloma.

Authors:  Jeong-Eun Yi; Sung-Eun Lee; Hae-Ok Jung; Chang-Ki Min; Ho-Joong Youn
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.